孫育良 熊小明 何本祥 宋偲茂 鄧軒賡 萬 躉 石華剛
(四川省骨科醫(yī)院脊柱科,成都 610041)
?
·臨床研究·
經皮椎體后凸成形術治療骨質疏松性椎體爆裂骨折*
孫育良①熊小明**何本祥①宋偲茂 鄧軒賡 萬 躉 石華剛
(四川省骨科醫(yī)院脊柱科,成都 610041)
目的 探討經皮椎體后凸成形術(percutaneous kyphoplasty,PKP)治療無神經脊髓癥狀的骨質疏松性椎體爆裂骨折的臨床療效及安全性。 方法 回顧性分析我院2013年1月~2015年6月采用雙側入路PKP治療骨質疏松性椎體爆裂骨折31例資料,記錄手術時間、透視次數、骨水泥用量、住院時間及骨水泥滲漏情況。術前、術后1天、末次隨訪采用疼痛視覺模擬評分(visual analog score,VAS)評估疼痛程度,Oswestry功能障礙指數(Oswestry disability index,ODI)評估患者日常生活功能;術前、術后1天及末次隨訪在X線側位片上測量傷椎高度和椎體后凸角,觀察術后1天及末次隨訪椎體高度恢復率和后凸角矯正率。 結果 手術均順利完成。術中骨水泥滲漏10例,均無相關神經或脊髓癥狀。術后隨訪12~21個月,(14.2±3.5)月。術后1天和末次隨訪的VAS評分[(2.5±0.8)分,(1.1±0.6)分]較術前[(6.8±0.9)分]明顯降低(t=20.393、30.178,P=0.000),末次隨訪的VAS評分較術后1天降低(t=8.237,P=0.000);術后1天和末次隨訪的ODI(37.2%±4.4%,17.6%±6.3%)較術前(72.9%±6.6%)明顯降低(t=25.053、33.575,P=0.000),末次隨訪的ODI較術后1天降低(t=14.140,P=0.000);術后1天和末次隨訪的傷椎高度[(18.8±1.5)mm,(18.5±1.6)mm]較術前[(15.6±1.5)mm]明顯增高(t=7.158、6.883,P=0.000),但末次隨訪的傷椎高度較術后1天無明顯變化(t=0.847,P=0.194);術后1天和末次隨訪的椎體后凸角(7.1°±2.5°,7.4°±2.8°)較術前(14.6°±2.6°)明顯減小(t=9.160、10.018,P=0.000),但末次隨訪的椎體后凸角較術后1天無明顯變化(t=0.800,P=0.936);末次隨訪椎體高度恢復率(49.5%±2.7%)較術后1天(50.0%±2.6%)無明顯變化(t=0.737,P=0.464);末次隨訪后凸角矯正率(50.7%±6.5%)較術后1天(51.9%±5.3%)無明顯差異(t=1.945,P=0.058)。隨訪過程中未見傷椎及鄰近椎體再骨折等并發(fā)癥。 結論 運用PKP治療無神經脊髓癥狀的老齡骨質疏松性椎體爆裂骨折,療效可靠,且相對安全。
經皮椎體后凸成形術; 骨質疏松; 椎體爆裂骨折
骨質疏松性椎體壓縮骨折(osteoporotic vertebral compression fracture, OVCF)是老年患者常見的骨折,經皮椎體成形術(percutaneous vertebroplaty,PVP)與經皮椎體后凸成形術(percutaneous kyphoplasty,PKP)是治療OVCF安全、有效的微創(chuàng)治療技術,能夠迅速緩解疼痛,使患者早期下床活動,恢復日常生活,是首選的治療方式[1~3]。在老年患者中無神經脊髓癥狀的骨質疏松性椎體爆裂骨折并不少見,保守治療效果欠佳。因椎體爆裂性骨折,椎體后緣破裂,椎管占位,增加骨填充劑滲漏的風險,曾被視為PKP手術的禁忌證[4~6],但并非絕對禁忌。近年來,國內外學者已開始探討應用PKP治療該類骨折,并取得了一定的療效,但其臨床療效和術中的安全性仍待進一步研究。本研究回顧性分析我院2013年1月~2015年6月31例PKP治療無神經脊髓癥狀的老年骨質疏松性椎體爆裂骨折的臨床資料,探討其療效和可行性。
1.1 一般資料
本組31例,男8例,女23例。年齡61~81歲,(69.9±6.4)歲。摔傷22例,車禍傷2例,彎腰提重物致傷3例,扭傷1例,自發(fā)性損傷3例。均有明顯腰背痛,5例腰背部軟組織損傷嚴重,7例強迫臥位。查體傷椎棘突有明顯的壓痛及叩擊痛,無下肢放射痛。術前常規(guī)行胸腰椎正側位X線片、傷椎CT、胸腰椎MRI檢查,提示椎體爆裂骨折,T91例,T113例,T129例,L111例,L23例,L34例,椎體壓縮程度9%~28%,椎體后凸角8°~19°,其中9例合并椎管占位(5%~30%)。均行骨密度測定,T值-3.7~-2.5。受傷后5~15天手術。
入選標準:①年齡>60歲;②脊柱外傷史或自發(fā)性骨折;③雙能X線骨密度測定,符合骨質疏松診斷標準[7]骨密度T值<-2.5;④X線側位片測量,傷椎前緣高度壓縮率<30%,椎體后凸角<20°;⑤CT檢查,骨折類型為爆裂性骨折,AO分型A3,椎管占位<30%,不伴有神經脊髓癥狀;⑥MRI提示椎體新鮮骨折為椎體內水腫。
排除標準:①伴有嚴重的心肺疾病、肝腎疾病及凝血障礙等;②伴顱腦損傷,胸、腹損傷;③椎體轉移性腫瘤及原發(fā)腫瘤等發(fā)生的病理性骨折。
1.2 方法
1.2.1 設備及器械 一次性椎體成形術器械包(山東冠龍醫(yī)療用品有限公司),包括帶鎖穿刺針、球表、帶表加壓器、骨水泥注入器、實體椎體鉆等;骨水泥為聚甲基丙烯酸甲酯(PMMA,德國賀利氏醫(yī)療有限公司);數字減影設備(荷蘭飛利浦公司)。
1.2.2 手術方法 全麻,俯臥位。麻醉完成后,行C形臂X線機透視術前定位傷椎,根據術前CT設計的穿刺路徑[8]定位畫出雙側穿刺進針點,穿刺時正位一般采用左側9點,右側3點位置。消毒鋪巾,在C形臂X線機引導下穿刺進針,針尖進入椎弓根后,將C形臂X線機調至側位,針尖達到椎體后緣之前,正位X線顯示針尖不應超過椎弓根影的內側緣。當針尖到達椎體前部1/3時,抽出穿刺針內芯,置入導針,沿導針置入擴張?zhí)坠芎凸ぷ魍ǖ?,同一球囊雙側依次撐開,碘海醇撐開球囊。球囊撐開后腔內填入一張撕成小塊的明膠海綿,將調制好的拉絲期骨水泥分段低壓緩慢推注,邊推注邊透視,當骨水泥彌散到椎體后1/3時,減少每次推注的量,增加透視次數。一旦發(fā)生滲漏,立即停止注射。當骨水泥彌散滿意,或后壁破裂患者達到椎體后1/3時,結束操作,取出穿刺針,無菌敷料覆蓋。
1.2.3 術后處理 術后心電監(jiān)護2小時,1~2天后戴腰圍下床活動。術后1天常規(guī)行胸腰椎正側位及胸部正位X線片、傷椎CT檢查,明確有無肺靜脈栓塞、骨水泥滲漏,觀察骨水泥彌散情況。繼續(xù)規(guī)律、系統性抗骨質疏松治療(骨化三醇軟膠囊、抗骨質疏松膠囊、醋酸鈣膠囊)。術后定期隨訪,行胸腰椎正側位X線片、傷椎CT檢查。
1.3 療效評價
1.3.1 疼痛視覺模擬評分(visual analog score,VAS)[9]術前、術后1天及末次隨訪,采用VAS評分對患者的疼痛程度進行評價,分值范圍0~10分,0分無痛,10分劇痛。
1.3.2 Oswestry功能障礙指數(Oswestry Disability Index,ODI)[10]術前、術后1天及末次隨訪,采用ODI對患者日常生活功能進行評估,包括疼痛(疼痛程度、痛對睡眠的影響),單項功能(提物、坐、站立、行走)和個人綜合功能(日?;顒幽芰?、性生活、社會活動和郊游)3大領域的評定。每項0~5分,分數越高表示功能障礙程度越重。將10個條目的答案相應得分累加后,計算其占10條目最高分合計(50分)的百分比,即為Oswestry功能障礙指數。
1.3.3 放射影像學評價 術前、術后1天及末次隨訪,在胸腰椎X線側位片上測量傷椎前壁高度H0,傷椎上位椎體前壁高度H1和下位椎體前壁高度H2,并計算術后1天和末次隨訪椎體高度恢復率,傷椎原始前壁高度H=(H1+H2)/2,椎體高度壓縮率=(H-H0)/H,椎體高度恢復率=(術前壓縮率-術后壓縮率)/術前壓縮率[11]。術前、術后1天及末次隨訪在X線側位片上測量椎體后凸角,并計算后凸角矯正率,傷椎上、下終板延長線的夾角即為椎體后凸角,后凸角矯正率=(術前后凸角-術后后凸角)/術前后凸角[12]。
1.4 統計學處理
2.1 手術情況
31例均順利完成手術,穿刺點距棘突的距離(3.8±0.4)cm,穿刺點出血量<10 ml。穿刺時間(6.4±1.3)min,手術時間(38.2±9.7)min;胸椎注入骨水泥量(4.4±0.9)ml,腰椎注入骨水泥量(4.7±0.9)ml。術中骨水泥滲漏10例,其中滲漏至椎體旁3例,椎前1例,上終板1例,下終板1例,椎體上終板和椎旁1例,椎管滲漏3例(滲漏骨水泥沿后縱韌帶分布),均無明顯神經脊髓癥狀,術后1天行胸部X線正位片,未發(fā)現肺栓塞。術后1~15天出院,隨訪12~21個月,(14.2±3.5)月,未見傷椎及鄰近椎體發(fā)生再骨折等并發(fā)癥。典型病例見圖1。
2.2 療效
術后1天VAS評分和ODI較術前明顯降低,傷椎高度增加,椎體后凸角減小;末次隨訪的VAS評分、ODI較術后1天進一步降低,而傷椎高度和椎體后凸角無明顯丟失;末次隨訪的椎體高度恢復率和后凸角矯正率較術后1天無明顯改變。見表1。
骨質疏松性椎體爆裂骨折在AO分型屬于A3型,伴有椎體后壁破裂,椎管占位。這類骨折目前主張經后路切開復位,椎管減壓,短節(jié)段骨水泥釘棒固定。然而高齡患者常合并內科疾病,無法耐受長時間的手術,并且術后臥床時間較長,骨量進一步丟失,加重骨質疏松程度,增加肺部、泌尿系感染的幾率。本組病例選擇上嚴格要求,當后凸角度>20°,椎管占位>30%,椎體前緣高度丟失>30%時,脊柱穩(wěn)定性較差,應用PKP治療,傷椎高度恢復有限,不能重建脊柱穩(wěn)定性,建議后路短節(jié)段骨水泥釘固定治療。適宜的病人選用PKP微創(chuàng)手術治療,不僅可縮短手術時間、術后臥床時間、住院時間,而且疼痛緩解迅速明顯。術后緩解疼痛的主要機制有:PMMA強度介于松質骨和皮質骨之間,抗壓強度大,骨水泥分布于傷椎骨裂縫中,穩(wěn)定椎體;PMMA聚合反應過程中釋放大量的熱量,其熱效應破壞椎體內血管和神經,從而緩解疼痛。
圖1 男,77歲,摔傷致腰背部疼痛伴活動受限1周入院,術前腰椎側位X線片和傷椎CT片(A、B)示L2椎體后壁破裂,椎管占位10%,L2椎體高度16.5 mm,后凸角10.8°,VAS 8分,ODI 69%。術前診斷:L2爆裂性骨折,骨質疏松癥。入院后3天在全麻下PKP手術,手術時間45 min,術中出血5 ml,注入骨水泥4.5 ml。術后1天腰椎側位X線片和傷椎CT(C、D)示骨水泥分布椎體前1/2,無骨水泥滲漏,L2椎體高度18.4 mm,后凸角5.2°,高度恢復率51.5%,后凸矯正率51.9%,VAS 4分,ODI 38%。術后4天出院。術后13個月隨訪時腰椎側位X線片和傷椎CT(E、F),椎體未見明顯塌陷和骨折,L2椎體高度18.2 mm,后凸角5.6°,高度恢復率45.9%,后凸矯正率48.1%,VAS 1分,ODI 19%
時間VAS評分(分)ODI(%)傷椎高度(mm)椎體后凸角(°)高度恢復率(%)后凸角矯正率(%)術前①6.8±0.972.9±6.615.6±1.514.6±2.6術后1天②2.5±0.837.2±4.418.8±1.57.1±2.550.0±2.651.9±5.3末次隨訪③1.1±0.617.6±6.318.5±1.67.4±2.849.5±2.750.7±6.5t1-2,P值20.393,0.00025.053,0.0007.158,0.0009.160,0.000t1-3,P值30.178,0.00033.575,0.0006.883,0.00010.018,0.000t2-3,P值8.237,0.00014.140,0.0000.847,0.1940.800,0.9360.737,0.4641.945,0.058
PKP治療骨質疏松性椎體壓縮性骨折最常見的并發(fā)癥是骨水泥滲漏[13],其中最嚴重的是椎管內滲漏。骨質疏松性椎體爆裂性骨折后壁破裂,椎管內滲漏的幾率更大,所以被視為PKP治療的禁忌證[4~6]。PKP治療骨質疏松性椎體爆裂性骨折,預防骨水泥的滲漏非常重要。選擇合適的手術時機,可減少骨水泥滲漏。董雙海等[14]的研究表明,傷后5~7天以后,尤其2周以后,經過臥床及體位復位骨折椎體內出血已止,凝血系統功能開始啟動,局部血腫機化、纖維化,可以部分修復椎體的四壁,可減少骨水泥滲漏。穿刺過程中,調節(jié)穿刺方向,盡可能地保證靠近椎體前1/3,椎體上下中部,偏上、偏下會增加椎間盤滲漏,椎間盤滲漏不僅加速椎間盤的退變[15],也增高鄰近椎體骨折的發(fā)生率[16]。高黏度的骨水泥流動性較差,術中注入高黏度骨水泥可以減少滲漏[4]。預防骨水泥滲漏最關鍵是術中堵塞滲漏通道,可分段推注骨水泥[17]:第一次推注少量骨水泥,封閉滲漏通道,待第一次推注的骨水泥干結后,再推注第二次骨水泥,這樣會大大減少骨水泥滲漏。我們認為,可以在推注骨水泥前用少量明膠海綿封堵加大的骨折縫隙,尤其是椎體前方,并且明膠海綿可以吸收骨水泥中的少量水分使骨水泥快速干結,減少骨水泥滲漏。操作時術中透視也非常重要,當骨水泥達到椎體后1/3時,可停止骨水泥推注[17]。剛推注的骨水泥具有一定的流動性,防止椎管內滲漏,不要過于追求骨水泥達到椎體后緣。一般認為,骨水泥的推注量與疼痛緩解效果無直接關系[18],相反,注入骨水泥越多,并發(fā)癥的幾率越高[19]。王磊升等[20]的臨床研究顯示,單側穿刺與雙側穿刺在椎體體積改善及疼痛緩解方面無明顯差異,但雙側穿刺可以減少推注時的壓力,減低穿刺風險和骨水泥滲漏,骨水泥易填充均勻。本研究選用雙側穿刺。
綜上所述,在熟練掌握PKP技術的基礎上,應用PKP治療老齡骨質疏松性椎體爆裂骨折,疼痛緩解明顯,傷椎高度基本恢復,并發(fā)癥相對較少,療效安全可靠。但目前應用PKP治療骨質疏松性椎體爆裂骨折的臨床報道較少,證據尚不充分[21,22]。本研究樣本數相對較少,隨訪時間短,近期療效可靠,遠期療效還有待于進一步長期隨訪研究。
1 周 毅,海 涌,蘇慶軍,等.椎體后凸成形術治療骨質疏松椎體壓縮性骨折療效分析.中國骨質疏松雜志,2012,18(5):429-433.
2 McConnell CT,Wippold FJ,Ray CE,et al.ACR appropriateness criteria management of vertebral compression fractures.J Am Coll Radiol,2014,11(8):757-763.
3 Bouza C,López-Cuadrado T,Almendro N,et al.Safety of balloon kyphoplasty in the treatment of osteoporotic vertebral compression fractures in Europe: a meta-analysis of randomized controlled trials.Eur Spine J,2015,24(4):715-723.
4 Walter J,Haciyakupoglu E,Waschke A,et al.Cement leakage as a possible complication of balloon kyphoplasty is there a difference between osteoporotic compression fractures (AO type A1) and incomplete burst fractures (AO type A3.1)? Acta Neurochir,2012,154(2):313-319.
5 Krappinger D,Kastenberger TJ,Schmid R.Augmented posterior Instrumentation for the treatment of osteoporotic vertebral body fractures.Opertive Orthop Traumat,2012,24(1):4-12.
6 Robinson Y,Heyde CE,Forsth P,et al.Kyphoplasty in osteoporotic vertebral compression fractures:guidelines and technical considerations.J Orthop Surg Res,2011,6:43-50.
7 中華醫(yī)學會骨質疏松和骨礦鹽疾病分會.原發(fā)性骨質疏松癥診治指南(2011年).中華骨質疏松和骨礦鹽疾病雜志,2011,4(1):2-17.
8 熊小明,宋偲茂,萬 躉,等.CT影像數據指導單側入路經皮椎體后凸成形術治療椎體壓縮性骨折.中國矯形外科雜志,2012,20(22):2035-2038.
9 謝曉明,肖建軍,羅錫勇.關節(jié)鏡手術為主綜合治療膝關節(jié)骨性關節(jié)炎臨床分析.中國現代醫(yī)生,2013,51(16):143-146.
10 劉 臻,邱 勇.Oswestry功能障礙指數在腰痛患者中的國際化應用現狀.中國脊柱脊髓雜志,2008,18(7):550-553.
11 顧宇彤,姜曉幸,董 健,等.經傷椎微創(chuàng)椎弓根釘內固定術治療胸腰椎爆裂性骨折.中國骨與關節(jié)外科,2014,7(5):408-411.
12 顧宇彤,梁朝革,張 亮,等.微創(chuàng)椎弓根釘內固定聯合磷酸鈣骨水泥椎體成形術治療胸腰椎爆裂性骨折.中國臨床醫(yī)學,2015,22(2):181-185.
13 Papanastassiou ID,Phillips FM,Van Meirhaeghe J,et al.Comparing effects of phoplasty vertebroplasty,and non-surgical management in a systematic review of randomized and non-randomized controlled studies.Eur Spine J,2012,21(9):1826-1843.
14 董雙海,田紀偉,王 雷,等.應用經皮椎體成形術及經皮椎體后凸成形術治療骨質疏松性椎體壓縮骨折.中華創(chuàng)傷雜志,2011,27(3):236-240.
15 陳 亮,楊惠林,唐天駟,等.椎體后凸成形術骨水泥椎間隙內滲漏的隨訪分析.中華骨科雜志,2008,28(12):1015-1018.
16 Lin EP,Ekholm S,Hiwatashi A,et al.Vertebroplasty: cement leakage into the disc increases the risk of new fracture of adjacent vertebral body.Am J Neuroradiol,2004,25(2):175-180.
17 Yang H,Pan J,Sun Z,et al.Percutaneous augmented Instrumentation of unstable thoracolumbar burst fractures:our experience in preventing cement leakage.Eur Spine J,2012,21:1410-1412.
18 Gill GB,Kuper M,Chin PC,et al.Comparing pain reduction following kyphoplasty and verteroplasty for osteoporotic vertebral compression fractures.Pain Physician,2007,10(4):583-590.
19 呂振華,楊中華,崔 青,等.小劑量骨水泥椎體成形術治療骨質疏松伴椎體壓縮性骨折.中國矯形外科雜志,2010,18(12):1043-1044.
20 王磊升,呂世橋,譚江威,等.單側經皮椎體后凸成形術治療有“真空裂隙征”的骨質疏松椎體骨折.中國微創(chuàng)外科雜志,2011,11(4):338-341.
21 Oh T,Scheer JK,Fakurnejad S,et al.Minimally invasive spinal surgery for the treatment of traumatic thoracolumbar burst fractures.J Clin Neurosci,2015,22(1):42-47.
22 盧公標,李咸周,杜 琳,等.經皮椎體后凸成形術治療原發(fā)骨質疏松性胸腰段椎體爆裂骨折的臨床療效觀察.中國微創(chuàng)外科雜志,2015,15(1):50-53.
(修回日期:2016-09-10)
(責任編輯:王惠群)
Percutaneous Kyphoplasty for Osteoporotic Vertebral Burst Fractures
SunYuliang,XiongXiaoming*,HeBenxiang,etal.
*DepartmentofSpineSurgery,SichuanProvinceOrthopedicsHospital,Chengdu610041,China
XiongXiaoming,E-mail: 2841710476@qq.com
Objective To investigate the clinical efficacy and safety of percutaneous kyphoplasty (PKP) in the treatment of osteoporotic vertebral burst fractures without neurological symptoms. Methods A retrospective analysis of 31 patients with osteoporotic vertebral burst fractures from January 2013 to June 2015 in our hospital treated by using bilateral approach PKP. The operation time, X-ray times, bone cement dosage, hospital days and bone cement leakage were recorded. The visual analogue scale (VAS) at preoperative, postoperative 1 day, and the last follow-up was used to evaluate the degree of pain. The Oswestry disability index (ODI) was used to assess the patient’s daily living functions. The measurement of vertebral height on lateral radiographs and vertebral kyphosis at preoperative, postoperative 1 day and the last follow-up was observed. The vertebral height restoration rate and the kyphosis correction rate at preoperative, postoperative 1 day and last follow-up were recorded. Results All the operations were successfully completed. There were 10 cases of bone cement leakage, without nerve or spinal cord symptoms. The patients were followed up for 12-21 months, with an average of (14.2±3.5) months. The VAS scores were significantly lower at postoperative 1 day and the last follow-up [(2.5±0.8) points, (1.1±0.6) points] than preoperative [(6.8±0.9) points] (t=20.393 and 30.178,P=0.000). The VAS scores were significantly lower at the last follow-up than that of postoperative 1 day (t=8.237,P=0.000). The ODI scores at postoperative 1 day and the last follow-up (37.2%±4.4%, 17.6%±6.3%) were significantly decreased as compared with the preoperative (72.9%±6.6%) (t=25.053 and 33.575,P=0.000). The ODI scores at the last follow-up were lower than that of the postoperative 1 day (t=14.140,P=0.000). The injured vertebral height at postoperative 1 day and the last follow-up [(18.8±1.5) mm, (18.5±1.6) mm] was significantly increased as compared with preoperative [(15.6±1.5) mm] (t=7.158 and 6.883,P=0.000). But at the last follow-up, the height of the injured vertebra was not significantly changed as compared with that of postoperative 1 day (t=0.847,P=0.194). The vertebral kyphosis at postoperative 1 day and the last follow-up (7.1°±2.5°, 7.4°±2.8°) was decreased significantly as compared with the preoperative (14.6°±2.6°) (t=9.160 and 10.018,P=0.000). But at the end of the follow-up the vertebral kyphosis had no obvious change as 1 day after surgery (t=0.800,P=0.936). The vertebral height restoration rate at the last of the follow-up (49.5%±2.7%) had no significant change as compared to the 1 day after operation (50.0%±2.6%) (t=0.737,P=0.464). The kyphosis correction rate at the last of the follow-up (50.7%±6.5%) had no significant difference as compared to the 1 day after operation (51.9%±5.3%) (t=1.945,P=0.058). No complications such as vertebral and adjacent vertebral fracture occurred during the follow-up. ConclusionPKP can be used in the treatment of osteoporotic vertebral burst fractures without neurological symptoms, which is reliable and relatively safe.
Percutaneous lumbar vertebral body; Osteoporosis; Vertebral burst fracture
四川省科技廳支撐項目(編號:2015SZ0190);國家科技支撐項目(編號:2012BAK21B01-02))
A
1009-6604(2016)12-1103-05
10.3969/j.issn.1009-6604.2016.12.011
2016-08-12)
**通訊作者,E-mail:2841710476@qq.com
①(成都體育學院,成都 610041)